UKHSA announces new effort to tackle hepatitis C
The agency has launched a whole genome sequencing service to monitor the virus
Read More
Tag: hepatitis C
Unitaid funds over £6m to Liverpool researchers to treat major diseases
The project aims to advance therapeutics for tuberculosis, malaria and hepatitis C in LMICs
Read More
US approves first all-genotype treatment for pediatric hepatitis C
AbbVie’s Mavyret treats all six genotypes of hepatitis C virus.
Read More
NHS, MSD collaborate to help eliminate hep C
The deal could help England become the first country in the world to eliminate hepatitis C.
Read More
NICE nod for Gilead’s pan-genotypic hepatitis C therapy
Gilead’s pan-genotypic treatment for hepatitis C Vosevi has won the National Institute for Health and Care Excellence’s seal of approval for use on the NHS.
Read More
NHS plans to be first to eliminate hepatitis C
NHS England has laid out plans for England to become the first country to eliminate hepatitis C, at least five years earlier than the World Health Organisation’s target date of 2030.
Read More
Scotland approves three new meds for NHS use
The Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C
Read More
Darzalex, Epclusa will be funded on NHS Scotland
Patients in Scotland with multiple myeloma and those with some types of hepatitis C have won NHS access to new treatment options after the Scottish Medicines Consortium backed routine use of Janssen’s Darzalex and Gilead’s Epclusa.
Read More
AbbVie’s pan-genotypic hep C therapy cleared in the US
AbbVie’s hepatitis C therapy Mavyret has picked up an approval in the US just days after having been green lighted by regulators in Europe.
Read More
New hepatitis C therapies approved in Europe
Patients with hepatitis C in Europe could soon gain access to two new pan-genotypic treatment options after the European Commission issued approval for AbbVie’s Maviret and Gilead’s Vosevi following an accelerated review.
Read More
US nod for Gilead’s pan-genotypic hep C pill
The US Food and Drug Administration has waved through Gilead’s new hepatitis C therapy Vosevi, offering adults with all genotypes of the condition a new treatment option in the form of three medicines in a single pill.
Read More
EMA advisors back eight medicines for approval
Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
